Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Astrana Health, Inc. (ASTH)
USD48.53
+0.89 (+1.87%)
US NASDAQ Healthcare Medical - Care Facilities
Address
1668 S. Garfield Avenue 91801
Alhambra, CA, US
Alhambra, CA, US
CEO
Brandon K. Sim
Website
astranahealth.com
IPO
2009-03-11
CIK 1083446 ISIN US03763A2078
Also trades on
NASDAQ Capital Market · AMEH (USD)
NASDAQ Capital Market · ASTH (USD)
Description
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverage—such as private plans, Medicare, Medicaid, and HMOs—but also extends care to uninsured individuals.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD48.53
+0.89 (+1.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
576.6K
Beta
0.89
Float Shares
39.07M
Free Float %
70.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.38% | +7.69% | +37.42% | +109.09% | +61.16% | +53.04% | +33.04% | +13.34% | +10.25% | +651.88% | +303.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
48.53
Low
37.00
-23.8%
Consensus
40.00
-17.6%
Median
40.00
-17.6%
High
45.00
-7.3%
DCF (Unlevered)
57.29
+18.0%
DCF (Levered)
278.78
+474.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
82% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 8 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
40.00
-17.6%
|
| Last Quarter | 1 |
40.00
-17.6%
|
| Last Year | 5 |
34.20
-29.5%
|
| All Time | 10 |
44.20
-8.9%
|
Quality scores
Altman Z-Score
2.69
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
2 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%+56.4% ★ Q1'26: +55.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-48.9% Q1'26: +107.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+1.4% ★ Q1'26: +6.6% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+2.5% Q1'26: +3.0% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+4.0% Q1'26: +6.5% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+2.4% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×8.68× Q1'26: 6.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
519.91M
est: 555.16M (-6.3%)
|
560.62M
est: 535.54M (+4.7%)
|
370.25M
est: 674.90M (-45.1%)
|
773.92M
est: 755.06M (+2.5%)
|
1.14B
est: 1.10B (+4.3%)
|
1.39B
est: 1.59B (-12.9%)
|
2.03B
est: 1.99B (+2.4%)
|
3.18B
est: 3.16B (+0.7%)
|
3.99B
3.97B – 4.00B
+26.1% YoY
|
4.37B
4.02B – 4.73B
+9.6% YoY
|
4.64B
4.64B – 4.64B
+6.3% YoY
|
5.02B
4.85B – 5.22B
+8.0% YoY
|
5.41B
5.23B – 5.63B
+7.9% YoY
|
| EBITDA |
102.49M
est: 51.88M (+97.5%)
|
48.85M
est: 50.05M (-2.4%)
|
29.74M
est: 63.07M (-52.8%)
|
100.66M
est: 70.56M (+42.7%)
|
112.08M
est: 102.55M (+9.3%)
|
123.69M
est: 135.62M (-8.8%)
|
141.84M
est: 169.25M (-16.2%)
|
124.27M
est: 269.33M (-53.9%)
|
339.58M
337.87M – 340.44M
+26.1% YoY
|
372.18M
342.26M – 402.97M
+9.6% YoY
|
395.65M
395.64M – 395.66M
+6.3% YoY
|
427.36M
413.19M – 444.53M
+8.0% YoY
|
461.27M
445.97M – 479.81M
+7.9% YoY
|
| EBIT |
83.19M
est: 39.22M (+112.1%)
|
30.57M
est: 37.83M (-19.2%)
|
11.39M
est: 47.68M (-76.1%)
|
83.14M
est: 53.34M (+55.9%)
|
94.54M
est: 77.52M (+22.0%)
|
105.94M
est: 110.51M (-4.1%)
|
113.92M
est: 137.92M (-17.4%)
|
78.53M
est: 219.46M (-64.2%)
|
276.71M
275.32M – 277.41M
+26.1% YoY
|
303.27M
278.89M – 328.36M
+9.6% YoY
|
322.40M
322.39M – 322.40M
+6.3% YoY
|
348.24M
336.69M – 362.23M
+8.0% YoY
|
375.87M
363.40M – 390.97M
+7.9% YoY
|
| Net Income |
10.84M
est: 23.63M (-54.1%)
|
14.12M
est: 19.29M (-26.8%)
|
-23.75M
est: 44.37M (-153.5%)
|
68.92M
est: 76.68M (-10.1%)
|
45.17M
est: 50.39M (-10.4%)
|
60.72M
est: 72.18M (-15.9%)
|
43.15M
est: 56.57M (-23.7%)
|
22.49M
est: 24.31M (-7.5%)
|
64.93M
57.56M – 68.11M
+167.1% YoY
|
94.89M
90.39M – 99.39M
+46.1% YoY
|
114.00M
104.40M – 114.81M
+20.1% YoY
|
138.73M
132.75M – 145.98M
+21.7% YoY
|
167.86M
160.62M – 176.63M
+21.0% YoY
|
| SGA |
47.24M
est: 38.55M (+22.6%)
|
41.48M
est: 37.18M (+11.6%)
|
15.59M
est: 46.86M (-66.7%)
|
62.08M
est: 52.42M (+18.4%)
|
77.67M
est: 76.19M (+1.9%)
|
112.60M
est: 118.85M (-5.3%)
|
154.11M
est: 148.32M (+3.9%)
|
217.26M
est: 236.03M (-8.0%)
|
297.59M
296.10M – 298.34M
+26.1% YoY
|
326.16M
299.94M – 353.15M
+9.6% YoY
|
346.73M
346.73M – 346.74M
+6.3% YoY
|
374.52M
362.10M – 389.57M
+8.0% YoY
|
404.24M
390.83M – 420.48M
+7.9% YoY
|
| EPS |
0.33
est: 0.49 (-32.7%)
|
0.41
est: 0.40 (+2.5%)
|
1.04
est: 0.92 (+13.0%)
|
1.57
est: 1.59 (-1.3%)
|
1.00
est: 1.05 (-4.3%)
|
1.30
est: 1.46 (-10.7%)
|
0.91
est: 1.14 (-19.9%)
|
0.46
est: 0.49 (-6.6%)
|
1.27
1.17 – 1.38
+158.4% YoY
|
1.91
1.83 – 2.01
+50.3% YoY
|
2.21
2.11 – 2.33
+15.5% YoY
|
2.81
2.69 – 2.96
+27.1% YoY
|
3.40
3.25 – 3.58
+21.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-15 | Baird | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
219.93M
OE per share TTM
4.46
Owner's Yield
12.48%
Maintenance CapEx ratio
88.08%
Maint CapEx / Avg PPE
4.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.33
Neutral
Ratio by volume
3.00
Bullish
Buys
4
Sells
3
Shares acquired
378.0K
Shares disposed
63.9K
Cash buys
—
Cash sales
—
Net activity
+314,081
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | Basho Chandan | Officer | F-InKind | D | Common Stock | 3,870 | 29.07 | 112.5K | 167,765 | D | ↗ |
| 2026-04-06 | Sim Kenneth T. | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 739,407 | D | ↗ |
| 2026-04-06 | Sim Brandon | Officer | A-Award | A | Common Stock | 201,056 | 0.00 | — | 1,246,385 | D | ↗ |
| 2026-04-06 | Lam Thomas S. | Director | A-Award | A | Common Stock | 41,667 | 0.00 | — | 465,657 | D | ↗ |
| 2026-04-02 | Basho Chandan | Officer | F-InKind | D | Common Stock | 2,092 | 25.05 | 52.4K | 171,635 | D | ↗ |
| 2026-04-01 | Kumar Dinesh M. | Officer | A-Award | A | Common Stock | 35,300 | 0.00 | — | 235,635 | D | ↗ |
| 2026-03-26 | Sobotka Glenn | Officer | F-InKind | D | Common Stock | 662 | 24.27 | 16.1K | 14,039 | D | ↗ |
| 2026-03-05 | Lam Thomas S. | Director | F-InKind | D | Common Stock | 9,266 | 25.07 | 232.3K | 423,990 | D | ↗ |
| 2026-03-05 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 1,697 | 25.07 | 42.5K | 200,335 | D | ↗ |
| 2026-03-05 | Basho Chandan | Officer | F-InKind | D | Common Stock | 1,240 | 25.07 | 31.1K | 173,727 | D | ↗ |
| 2026-02-02 | Sim Brandon | Officer | M-Exempt | A | Common Stock | 21,334 | 23.24 | 495.8K | 1,045,329 | D | ↗ |
| 2026-01-23 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 10,759 | 27.16 | 292.2K | 202,032 | D | ↗ |
| 2026-01-13 | Schmidt David | Director | F-InKind | D | Common Stock | 4,269 | 27.12 | 115.8K | 31,494 | D | ↗ |
| 2026-01-01 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 5,102 | 24.81 | 126.6K | 212,791 | D | ↗ |
| 2025-12-08 | Lam Thomas S. | Director | M-Exempt | A | Common Stock | 29,502 | 17.78 | 524.5K | 459,122 | D | ↗ |
| 2025-11-10 | Sim Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 29,502 | 17.78 | 524.5K | 639,407 | D | ↗ |
| 2025-11-10 | Mazdyasni Matthew | Director | M-Exempt | A | Common Stock | 20,000 | 18.20 | 364.0K | 34,763 | D | ↗ |
| 2025-11-07 | Kitayama Mitchell W | Director | M-Exempt | A | Common Stock | 12,000 | 18.20 | 218.4K | 27,846 | D | ↗ |
| 2025-11-03 | Marsh Linda | Director | M-Exempt | D | Stock Option (right to Buy) | 20,000 | 18.20 | 364.0K | 0 | D | ↗ |
| 2025-10-02 | Basho Chandan | Officer | F-InKind | D | Common Stock | 1,979 | 27.77 | 55.0K | 174,967 | D | ↗ |
| 2025-09-15 | Kitayama Mitchell W | Director | D-Return | D | Common Stock | 8,000 | 30.23 | 241.8K | 21,060 | D | ↗ |
| 2025-09-05 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 1,694 | 29.70 | 50.3K | 217,893 | D | ↗ |
| 2025-09-05 | Basho Chandan | Officer | F-InKind | D | Common Stock | 1,694 | 29.70 | 50.3K | 176,946 | D | ↗ |
| 2025-09-02 | Schmidt David | Director | D-Return | D | Common Stock | 20,000 | 27.76 | 555.2K | 15,763 | D | ↗ |
| 2025-08-13 | Chiang John | Director | M-Exempt | A | Common Stock | 20,000 | 18.20 | 364.0K | 43,132 | D | ↗ |
| 2025-07-01 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 6,831 | 25.06 | 171.2K | 218,811 | D | ↗ |
| 2025-06-11 | Schmidt David | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 15,763 | D | ↗ |
| 2025-06-11 | Mazdyasni Matthew | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 14,763 | D | ↗ |
| 2025-06-11 | Marsh Linda | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 83,641 | D | ↗ |
| 2025-06-11 | Kitayama Mitchell W | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 21,060 | D | ↗ |
| 2025-06-11 | Dai, Weili | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 13,663 | D | ↗ |
| 2025-06-11 | Chiang John | Director | A-Award | A | Common Stock | 6,449 | 0.00 | — | 23,132 | D | ↗ |
| 2025-06-04 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 1,656 | 25.06 | 41.5K | 225,642 | D | ↗ |
| 2025-05-16 | Basho Chandan | Officer | F-InKind | D | Common Stock | 10,035 | 27.18 | 272.8K | 178,640 | D | ↗ |
| 2025-04-29 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 828 | 31.15 | 25.8K | 227,298 | D | ↗ |
| 2025-04-14 | Basho Chandan | Officer | F-InKind | D | Common Stock | 2,683 | 34.05 | 91.4K | 188,675 | D | ↗ |
| 2025-04-02 | Basho Chandan | Officer | F-InKind | D | Common Stock | 1,394 | 30.02 | 41.8K | 191,358 | D | ↗ |
| 2025-03-26 | Sobotka Glenn | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-05 | Sim Brandon | Officer | F-InKind | D | Common Stock | 105,795 | 27.19 | 2.88M | 1,023,219 | D | ↗ |
| 2025-03-05 | Lam Thomas S. | Director | F-InKind | D | Common Stock | 9,235 | 27.19 | 251.1K | 429,620 | D | ↗ |
| 2025-03-05 | Kumar Dinesh M. | Officer | A-Award | A | Common Stock | 26,701 | 0.00 | — | 235,992 | D | ↗ |
| 2025-03-05 | Basho Chandan | Officer | A-Award | A | Common Stock | 26,701 | 0.00 | — | 192,752 | D | ↗ |
| 2025-02-15 | Sim Kenneth T. | Director / Officer | J-Other | D | Common Stock | 699,896 | 0.00 | — | 6,132,802 | I | ↗ |
| 2025-02-15 | Lam Thomas S. | Director | J-Other | D | Common Stock | 699,896 | 0.00 | — | 6,132,802 | I | ↗ |
| 2025-02-15 | ALLIED PHYSICIANS OF CALIFORNIA, A PROFESSIONAL MEDICAL Corp | 10% Owner | J-Other | D | Common Stock | 699,896 | 0.00 | — | 6,132,802 | D | ↗ |
| 2025-01-23 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 7,210 | 37.96 | 273.7K | 209,291 | D | ↗ |
| 2025-01-17 | ALLIED PHYSICIANS OF CALIFORNIA, A PROFESSIONAL MEDICAL Corp | 10% Owner | D-Return | D | Common Stock | 300,000 | 35.17 | 10.55M | 6,832,698 | D | ↗ |
| 2025-01-01 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 967 | 31.53 | 30.5K | 215,872 | D | ↗ |
| 2024-12-10 | Kitayama Mitchell W | Director | D-Return | D | Common Stock | 5,100 | 43.09 | 219.8K | 14,611 | D | ↗ |
| 2024-11-30 | Vong John | Officer | F-InKind | D | Common Stock | 134 | 43.25 | 5.8K | 17,520 | D | ↗ |
| 2024-11-22 | Kitayama Mitchell W | Director | M-Exempt | A | Common Stock | 3,409 | 18.41 | 62.8K | 21,201 | D | ↗ |
| 2024-11-19 | Chiang John | Director | M-Exempt | D | Stock Option (right to buy) | 1,515 | 18.41 | 27.9K | 0 | D | ↗ |
| 2024-11-18 | Sim Kenneth T. | Director / Officer | M-Exempt | A | Common Stock | 28,046 | 18.65 | 523.1K | 609,905 | D | ↗ |
| 2024-11-12 | Vong John | Officer | F-InKind | D | Common Stock | 636 | 42.91 | 27.3K | 17,654 | D | ↗ |
| 2024-11-08 | Sim Kenneth T. | Director / Officer | A-Award | A | Common Stock | 133,333 | 0.00 | — | 581,859 | D | ↗ |
| 2024-11-08 | Sim Brandon | Officer | A-Award | A | Common Stock | 34,386 | 0.00 | — | 983,372 | D | ↗ |
| 2024-11-08 | Lam Thomas S. | Director | A-Award | A | Common Stock | 26,667 | 0.00 | — | 438,855 | D | ↗ |
| 2024-11-08 | Kumar Dinesh M. | Officer | A-Award | A | Common Stock | 67,238 | 0.00 | — | 216,839 | D | ↗ |
| 2024-11-08 | Basho Chandan | Officer | A-Award | A | Common Stock | 15,510 | 0.00 | — | 166,742 | D | ↗ |
| 2024-10-02 | Sim Brandon | Officer | F-InKind | D | Common Stock | 2,626 | 57.87 | 152.0K | 948,986 | D | ↗ |
| 2024-09-10 | Marsh Linda | Director | F-InKind | D | Common Stock | 3,522 | 47.93 | 168.8K | 77,192 | — | ↗ |
| 2024-09-10 | Kitayama Mitchell W | Director | M-Exempt | A | Common Stock | 11,000 | 15.35 | 168.9K | 21,314 | — | ↗ |
| 2024-09-09 | Lam Thomas S. | Director | M-Exempt | A | Common Stock | 28,046 | 18.65 | 523.1K | 409,901 | — | ↗ |
| 2024-09-09 | Chiang John | Director | M-Exempt | A | Common Stock | 11,000 | 15.35 | 168.9K | 19,414 | — | ↗ |
| 2024-08-16 | Schmidt David | Director | D-Return | D | Common Stock | 14,409 | 49.76 | 717.0K | 9,314 | — | ↗ |
| 2024-08-14 | Schmidt David | Director | M-Exempt | D | Stock Option (right to buy) | 11,000 | 15.35 | 168.9K | 0 | — | ↗ |
| 2024-08-13 | Schmidt David | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 9,314 | — | ↗ |
| 2024-08-13 | Mazdyasni Matthew | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 8,314 | — | ↗ |
| 2024-08-13 | Marsh Linda | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 69,714 | — | ↗ |
| 2024-08-13 | Kitayama Mitchell W | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 10,314 | — | ↗ |
| 2024-08-13 | Dai, Weili | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 7,214 | — | ↗ |
| 2024-08-13 | Chiang John | Director | A-Award | A | Common Stock | 3,564 | 0.00 | — | 8,414 | — | ↗ |
| 2024-08-01 | Vong John | Officer | F-InKind | D | Common Stock | 67 | 51.57 | 3.5K | 18,290 | — | ↗ |
| 2024-08-01 | Kumar Dinesh M. | Officer | F-InKind | D | Common Stock | 794 | 51.57 | 40.9K | 149,601 | — | ↗ |
| 2024-07-11 | Vong John | Officer | F-InKind | D | Common Stock | 336 | 45.00 | 15.1K | 18,357 | — | ↗ |
| 2024-05-16 | Basho Chandan | Officer | F-InKind | D | Common Stock | 7,051 | 41.13 | 290.0K | 151,232 | — | ↗ |
| 2024-05-12 | Vong John | Officer | F-InKind | D | Common Stock | 636 | 38.89 | 24.7K | 18,617 | — | ↗ |
| 2024-04-14 | Basho Chandan | Officer | F-InKind | D | Common Stock | 7,993 | 40.72 | 325.5K | 158,283 | — | ↗ |
| 2024-04-02 | Sim Brandon | Officer | A-Award | A | Common Stock | 86,305 | 0.00 | — | 988,925 | — | ↗ |
| 2024-04-02 | Basho Chandan | Officer | A-Award | A | Common Stock | 15,692 | 0.00 | — | 172,783 | — | ↗ |
| 2024-03-29 | Sim Brandon | Officer | F-InKind | D | Common Stock | 37,957 | 41.99 | 1.59M | 950,968 | — | ↗ |
| 2024-03-29 | Basho Chandan | Officer | F-InKind | D | Common Stock | 6,507 | 41.99 | 273.2K | 166,276 | — | ↗ |
Executive team
Top executives
EBIT / Employee
41.3K
Shares Outstanding
55.71M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brandon K. Sim, M.S. Chief Executive Officer | 850.0K | — | 12.00M | — | 2.06M | 21.1K | 14.93M | 80.37% | ↗ |
| 2 | 2025 | Dinesh Kumar, M.D. Chief Medical Officer | 700.0K | — | 2.20M | — | 1.36M | 27.5K | 4.28M | 51.36% | ↗ |
| 3 | 2025 | Chandan Basho, M.B.A. Chief Financial Officer and Chief Operating Officer | 678.1K | — | 2.20M | — | 979.9K | 9.1K | 3.87M | 56.89% | ↗ |
| 4 | 2025 | Kenneth Sim, M.D. Executive Chairman | 950.0K | 100.0K | — | — | — | 24.2K | 1.07M | 0.00% | ↗ |
| 5 | 2024 | Brandon K. Sim, M.S. Chief Executive Officer | 813.5K | — | 15.89M | — | 1.52M | 12.5K | 18.24M | 87.12% | ↗ |
| 6 | 2024 | Dinesh Kumar, M.D. Chief Medical Officer | 678.0K | — | 8.70M | — | 1.00M | 14.1K | 10.39M | 83.68% | ↗ |
| 7 | 2024 | Kenneth Sim, M.D. Executive Chairman | 950.0K | — | 9.39M | — | — | 20.9K | 10.36M | 90.63% | ↗ |
| 8 | 2024 | Chandan Basho, M.B.A. Chief Financial Officer and Chief Operating Officer | 556.2K | — | 4.21M | — | 688.2K | 9.0K | 5.46M | 77.05% | ↗ |
| 9 | 2024 | Thomas Lam, M.D., M.P.H. Vice Chairman (former Co-Chief Executive Officer) | 950.0K | — | 1.88M | — | — | 14.7K | 2.84M | 66.07% | ↗ |
| 10 | 2024 | Albert Young, M.D., M.P.H. SVP of Health Affairs (former Chief Administrative Officer) | 400.0K | 39.0K | — | — | — | 13.3K | 452.3K | 0.00% | ↗ |
| 11 | 2023 | Brandon K. Sim, M.S. Chief Executive Officer | 712.3K | 1.09M | 12.50M | — | — | 11.5K | 14.31M | 87.34% | ↗ |
| 12 | 2023 | Chandan Basho, M.B.A. Chief Financial Officer and Chief Operating Officer | 415.4K | 675.0K | 4.60M | — | — | 8.7K | 5.70M | 80.71% | ↗ |
| 13 | 2023 | Kenneth Sim, M.D. Executive Chairman | 950.0K | 1.00M | 3.25M | — | — | 20.1K | 5.22M | 62.28% | ↗ |
| 14 | 2023 | Thomas Lam, M.D., M.P.H. Vice Chairman (former Co-Chief Executive Officer) | 950.0K | 1.00M | 3.25M | — | — | 14.1K | 5.22M | 62.36% | ↗ |
| 15 | 2023 | Albert Young, M.D., M.P.H. SVP of Health Affairs (former Chief Administrative Officer) | 400.0K | 150.0K | — | — | — | 12.8K | 562.8K | 0.00% | ↗ |
| 16 | 2022 | Brandon K. Sim, M.S. Chief Executive Officer | 670.0K | 1.00M | 13.57M | — | — | 64.9K | 15.30M | 88.66% | ↗ |
| 17 | 2022 | Chandan Basho, M.B.A. Chief Financial Officer and Chief Operating Officer | 195.0K | 385.0K | 3.31M | 213.4K | — | 1.4K | 4.10M | 85.83% | ↗ |
| 18 | 2022 | Kenneth Sim, M.D. Executive Chairman | 950.0K | 450.0K | — | — | — | 94.0K | 1.49M | 0.00% | ↗ |
| 19 | 2022 | Thomas Lam, M.D., M.P.H. Vice Chairman (former Co-Chief Executive Officer) | 950.0K | 450.0K | — | — | — | 87.7K | 1.49M | 0.00% | ↗ |
| 20 | 2022 | Albert Young, M.D., M.P.H. SVP of Health Affairs (former Chief Administrative Officer) | 400.0K | 150.0K | — | — | — | 23.7K | 573.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brandon Sim | President & Chief Executive Officer | 3M | male |
| Dinesh Kumar | Chief Medical Officer | 2M | — |
| Chandan Basho | Chief Financial Officer, Chief Operating Officer & Corporate Secretary | 2M | male |
| Kenneth T. Sim | Co-Founder & Executive Chairman | 1M | — |
| Thomas S. Lam | Co-Founder & Vice Chairman | 985.5K | — |
| WaiChow Young | Senior Vice President of Health Affairs | 452.3K | — |
| Jeremy R. Jackson | Chief Quality Officer | — | — |
| Neil Ahuja | President of Provider Solutions | — | male |
| Rita Pew | Chief People Officer | — | female |
| Jaime Melkonoff | President of AstranaCare - Texas | — | female |
| Glenn W. Sobotka | Chief Accounting Officer & Principal Accounting Officer | — | male |
ESG Rating
ESG Score History MEDICAL - CARE FACILITIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
